Central nervous system lymphoma
Not recruitingStudy on Methotrexate, Tafasitamab, Lenalidomide, and Rituximab for Patients with Primary Central Nervous System Lymphoma Not Eligible for Stem Cell Transplant
Study on Methotrexate, Tafasitamab, Lenalidomide, and Rituximab for Patients with Primary Central Nervous System Lymphoma Not Eligible for Stem Cell Transplant
- Disease:Central nervous system lymphoma
- Substances:LenalidomideMethotrexate+2
Germany- Participants:18–64 years · 65+ years
- Substances:Lenalidomide
- Sponsor:University Of Cologne













